Latest news
Iconovo signs an agreement with Stevanato Group regarding the manufacture, sale and distribution of ICOcap
The inhalation developer Iconovo AB (publ) announced today that the company has signed an agreement with the multinational Stevanato Group, headquartered…
Dr Orest Lastow is lecturing at Dry Powder Inhalers Annual Conference London 20-21 June 2018
The second generation of DPIs have become either established on the market or are a significant way along the approval process. These have been a great…
Press releases
Aug 30, 2023, 14:00
News
IR
Swedish
Corporate Action
Other
Aug 29, 2023, 09:35
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
General meeting
Raport bolagsstämman
Aug 22, 2023, 09:00
News
IR
Swedish
Corporate Action
Other
mfn-cus-disclaimer
Aug 22, 2023, 09:00
News
IR
English
Corporate Action
Other
mfn-cus-disclaimer
Aug 17, 2023, 08:15
News
IR
Swedish
Regulatory
MAR
Corporate Action
Other
Aug 17, 2023, 08:15
News
IR
English
Regulatory
MAR
Corporate Action
Other
Aug 16, 2023, 08:15
News
IR
Swedish
Regulatory
MAR
Corporate Action
Other
Aug 16, 2023, 08:15
News
IR
English
Regulatory
MAR
Corporate Action
Other
Aug 09, 2023, 18:00
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
General meeting
Notice
Jul 14, 2023, 08:30
News
IR
Swedish
Regulatory
MAR
Report
Interim
Q2
Jul 13, 2023, 08:15
News
IR
English
Regulatory
MAR
Corporate Action
Other
Jul 13, 2023, 08:15
News
IR
Swedish
Regulatory
MAR
Corporate Action
Other
Jun 19, 2023, 08:15
News
IR
English
Corporate Action
Other
Jun 19, 2023, 08:15
News
IR
Swedish
Corporate Action
Other
Jun 09, 2023, 08:30
News
IR
English
Corporate Action
Other
Jun 09, 2023, 08:30
News
IR
Swedish
Corporate Action
Other
Jun 01, 2023, 08:45
News
IR
Swedish
Corporate Action
Other
Jun 01, 2023, 08:45
News
IR
English
Corporate Action
Other
May 26, 2023, 16:50
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
General meeting
Raport bolagsstämman
Possessing a unique combination
of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.
ICONOVO AB
VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B
POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 62 LUND
Sweden
CONTACT
Phone: +46 46 275 67 77
Director Business Development and Alliances
Måns Österberg
Mail: mans.osterberg@iconovo.se
CEO
Anders Månsson
Mail: anders.mansson@iconovo.se
Press releases
Follow us on Linkedin
